ASPIRE BIOPHARMA HOLDINGS, INC. Investing Cash Flow
ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP) reported Investing Cash Flow of $13.78 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2025-04-07
- ASPIRE BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was $0.00.
- ASPIRE BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ASPIRE BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2023-12-31 was $0.00.
- ASPIRE BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2023-09-30 was $632.97K.
- ASPIRE BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $13.78M, a 95.16% decline from fiscal 2023.
- ASPIRE BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $284.92M.
- ASPIRE BIOPHARMA HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$294.69M.
| Period end | Net Cash Provided by (Used in) Investing Activities 2 month | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | $0.00 derived: sum of 2 quarters · filed 2025-04-07 | $13.78M 10-K · filed 2025-04-07 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $13.78M 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $13.78M 10-Q · filed 2024-08-16 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | $632.97K derived: sum of 2 quarters · filed 2025-04-07 | $284.92M 10-K · filed 2025-04-07 | ||
| 2023-09-30 | $632.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $284.92M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $284.28M 10-Q · filed 2024-08-16 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $0.00 derived: sum of 3 quarters · filed 2024-03-11 | -$294.69M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | -$294.69M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$294.69M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$294.69M 10-Q · filed 2023-05-11 | ||||
| 2021-03-31 | $165.96K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |